Serrapeptase

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Serrapeptase
Accession Number
DB13131
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Serratiopeptidase
Categories
UNII
NL053ABE4J
CAS number
95077-02-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Serrapeptase.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 16-Bromoepiandrosterone.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 19-norandrostenedione.
5-androstenedioneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with 5-androstenedione.
AceclofenacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Acemetacin.
AlclofenacThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alclofenac.
AldosteroneThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Aldosterone.
AliskirenSerrapeptase may decrease the antihypertensive activities of Aliskiren.
AlminoprofenThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alminoprofen.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911427
Wikipedia
Serrapeptase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentInflammatory Reaction / Swelling / Trismus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 21:33 / Updated on October 01, 2018 15:26